Literature DB >> 12366607

Residual insulin secretion is not coupled to a maintained glucagon response to hypoglycaemia in long-term type 1 diabetes.

S Sjöberg1, B Ahrén, J Bolinder.   

Abstract

OBJECTIVES: To evaluate the influence of residual beta-cell function on glucagon secretion and glucose counter-regulation following hypoglycaemia in type 1 diabetes. DESIGN AND
SUBJECTS: The hormonal counter-regulatory responses to standardized insulin-induced hypoglycaemia were investigated, 18 patients with type 1 diabetes of long duration and 12 healthy subjects were investigated. Nine of the diabetic patients (diabetes duration 17 +/- 1 years) had residual insulin secretion, as reflected by persistent urinary C-peptide excretion. The other nine diabetic patients (diabetes duration 21 +/- 1 years) were C-peptide negative.
RESULTS: Similar hypoglycaemic nadirs were found in all groups (2.1-2.3 mmol L-1), whereas the recovery of plasma glucose levels was delayed similarly in the diabetic groups. In the control subjects, plasma glucagon increased ( approximately 50%). No significant glucagon response was registered in either of the two diabetic groups. The maximum plasma adrenaline and pancreatic polypeptides (PP) responses to hypoglycaemia were comparable in the two diabetic patient groups; the peak values being lower (P < 0.05) than in the controls. Plasma noradrenaline, growth hormone and cortisol responses to hypoglycaemia were similar in all three groups.
CONCLUSION: Residual beta-cell function in patients with long-term type 1 diabetes is not accompanied by preservation of the glucagon response to hypoglycaemia. As the two markers of autonomic function (adrenaline and PP) were similarly reduced in the two diabetic groups, the findings instead favour the concept that the defective glucagon secretory response to hypoglycaemia is because of autonomic nervous dysfunction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12366607     DOI: 10.1046/j.1365-2796.2002.01043.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  6 in total

1.  Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes.

Authors:  P A Bakhtiani; J El Youssef; A K Duell; D L Branigan; P G Jacobs; M R Lasarev; J R Castle; W K Ward
Journal:  J Diabetes Complications       Date:  2014-09-16       Impact factor: 2.852

2.  The UVA/PADOVA Type 1 Diabetes Simulator: New Features.

Authors:  Chiara Dalla Man; Francesco Micheletto; Dayu Lv; Marc Breton; Boris Kovatchev; Claudio Cobelli
Journal:  J Diabetes Sci Technol       Date:  2014-01-01

Review 3.  Minimizing morbidity of hypoglycemia in diabetes: a review of mini-dose glucagon.

Authors:  Stephanie T Chung; Morey W Haymond
Journal:  J Diabetes Sci Technol       Date:  2014-08-26

4.  High residual C-peptide likely contributes to glycemic control in type 1 diabetes.

Authors:  Michael R Rickels; Carmella Evans-Molina; Henry T Bahnson; Alyssa Ylescupidez; Kristen J Nadeau; Wei Hao; Mark A Clements; Jennifer L Sherr; Richard E Pratley; Tamara S Hannon; Viral N Shah; Kellee M Miller; Carla J Greenbaum
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

5.  Early loss of the glucagon response to hypoglycemia in adolescents with type 1 diabetes.

Authors:  Aris Siafarikas; Robert J Johnston; Max K Bulsara; Peter O'Leary; Timothy W Jones; Elizabeth A Davis
Journal:  Diabetes Care       Date:  2012-06-14       Impact factor: 19.112

6.  Role of counterregulatory hormones for glucose metabolism in children and adolescents with type 1 diabetes.

Authors:  Akiko Nishimura; Kisho Kobayashi; Hideaki Yagasaki; Tomohiro Saito; Kenjiro Nagamine; Yumiko Mitsui; Mie Mochizuki; Kazumasa Satoh; Koji Kobayashi; Tomoaki Sano; Masanori Ohta; Hideo Cho; Kenji Ohyama
Journal:  Clin Pediatr Endocrinol       Date:  2011-11-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.